Drug · DIN 02468093
SUBOXONE
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since February 14, 2018; first marketed February 14, 2018.
- Drug Identification Number (DIN)
- 02468093
- Company (DIN owner)
- Indivior Uk LimitedHull, United Kingdom
- Schedule
- Narcotics (CDSA I)
- Dosage form
- Tablet
- Route
- Sublingual
- Therapeutic class (ATC)
- Buprenorphine, combinations N07BC51
- Class
- Human
- Record last updated
- March 22, 2025
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| BUPRENORPHINE (BUPRENORPHINE HYDROCHLORIDE) | 16 MG | |
| NALOXONE (NALOXONE HYDROCHLORIDE DIHYDRATE) | 4 MG |
Notices of Compliance
Health Canada approvals that name this DIN.
- September 1, 2017: NOC 19752Supplement to a New Drug Submission (SNDS) · Addition of new tablet strengths
Recalls and safety alerts that mention it
Health Canada’s recall notices do not carry licence numbers, so these are matched by name: notices whose title or product names “suboxone”. A notice may cover another product or only some lots: read it to see what it covers.
Other DINs named SUBOXONE
- DIN 02295695 · Marketed
- DIN 02295709 · Marketed
- DIN 02468085 · Marketed
- DIN 02502313 · Marketed
- DIN 02502321 · Marketed
- DIN 02502348 · Marketed
- DIN 02502356 · Marketed